Vilka är öppettiderna?

Måndag 09:00 - 17:00 Tisdag 09:00 - 17:00 Onsdag 09:00 - 17:00 Torsdag 09:00 - 17:00 Fredag 09:00 - 17:00

AMRA Medical

Hem
Sverige
Linköping
AMRA Medical

AMRA is the first to transform MR images into precise body composition measurements using a cloud-based, computer-aided service and a rapid MRI scan.

AMRA is the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service and a rapid MRI scan. Our imaging-based biomarkers (visceral fat, abdominal subcutaneous fat, liver fat, intramuscular fat, muscle group volumes, single muscle volumes, etc) are designed to play a long-term role in clinical trial development, research studies

, and preventive care in a clinical setting. We collaborate with world-leading pharma, biobanks, research institutions, and hospitals, aiding in the advancement of metabolic research and its therapeutic application. With accurate knowledge about our bodies, we assist global medical leaders in predicting and preventing illnesses related to obesity-related and other metabolic disease, including diabetes, obesity, cardiovascular disease, liver disease, sarcopenia, musculoskeletal disorders, and more. Our Vision is a new, fundamental way of thinking about health. We provide knowledge to the medical community so that every individual can become — and stay — healthy.

09/07/2025

AMRA Headlines as Lead Partner @ The 3rd Annual Obesity and Weight Loss Drug Development Summit!

📅 SAVE THE DATE: July 14th - 16th, 2025 | Boston, MA

We are absolutely thrilled to join the 3rd Annual Obesity and Weight Loss Drug Development Summit as the 2025 Lead Partner! Join our CEO, Dr. Olof Dahlqvist Leinhard, as he discusses how transformative MRI-based body composition methods and AMRA’s unique biomarkers are redefining obesity drug trials:

🔬 "MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss"
👨🏻‍🔬 Olof Dahlqvist Leinhard, PhD
🗓 July 15th, 9:00am

The Obesity and Weight Loss Drug Development Summit, entering its third year, gathers the leading pharma, biotech, clinical, and academic thought partners to chart the next wave of obesity therapeutics—from navigating new guidelines to advancing personalized, muscle-preserving and side-effect-sparing treatment strategies.

As the obesity treatment landscape has evolved significantly over the past few years with the advent of GLP-1-based therapies, AMRA has been involved in many high-profile studies that evaluate the effects of anti-obesity medications on fat distribution and muscle composition. AMRA’s novel body fat and muscle volume z-score biomarkers uncover and help quantify these deeper-than-surface-level changes in body composition, and deepening insights within obesity treatment differentiation.

Powered by AMRAⓇ Researcher, the body fat and muscle volume z-score biomarkers provide reproducible and reliable measures of fat distribution and muscle composition, determining how far each participant deviates from the expected fat or muscle volume for someone with their s*x and body mass index.

This new, s*x-, height-, weight-, and BMI-invariant approach to quantifying body composition has made strides in helping drug manufacturers retrieve better insights during their trials – particularly by enabling a shift in focus while designing trials – from simply targeting great weight reduction to achieving a high-quality weight reduction. Providing measures, such as the z-scores, that assist manufacturers in developing a more nuanced understanding of how their interventions might affect body composition beyond simple weight loss adds a new tool to allow them to differentiate their products in the fast-moving, ever-changing GLP-1 landscape of today.

We are proud to be this year’s Summit Lead Partner, a testament to our commitment to doing our part in shaping the future of the obesity and weight loss drug development landscape. We can’t wait to see you there!

📥 Download the event guide here: https://shorturl.at/lSq18

Interested in MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health? Read more: https://shorturl.at/8iuEQ

25/06/2025

Do you want to be part of a dedicated, professional, and visionary team – shaping the future of precision health?

🚀 We are hiring! As Scientific Writer, you will be an integral part of AMRA’s Science team, contributing to the development of scientific publications, abstracts, and communication materials that highlight the company’s unique technology and research.

You’ll collaborate closely with clinical scientists, statisticians, and the BD/marketing team to create impactful, high-quality content that supports both academic credibility and commercial growth.

👉 Apply here: https://peaksearch.positionett.se/assignment.php?id=1284

19/06/2025

AMRA Medical To Attend the ADA’s 85th Scientific Sessions in Chicago, IL!

We’re excited to share that AMRA Medical will be in attendance at the Diabetes Association’s 85th “Scientific Sessions” meeting, from June 20th-23rd.

The ADA’s Scientific Sessions conference is the premier diabetes conference where leading experts and peers will share the latest findings in research, prevention, and care. We’re looking forward to learning more about what’s new in the field, as we continue to pioneer biomarker development for metabolic disease research efforts, including Type II Diabetes.

Coming to the 85th Scientific Sessions conference as well?

Reach out to info@amramedical.com, or meet Leanna Kellerman, Chief Globalization Officer at the venue if you’d like to learn more about AMRA and what we can do to help push your diabetes research efforts forward. We’d love to see you there!

19/06/2025

AMRA Shares Latest Findings at the FSHD Society’s 2025 International Research Congress

AMRA Medical was thrilled to attend the 2025 International Research Congress, hosted by the FSHD Society! The conference, held last week in Amsterdam, NL, remains the premier global forum dedicated solely to facioscapulohumeral muscular dystrophy (FSHD) research.

The event once again played a catalytic role in translating ideas into potential therapies, uniting leading clinicians, researchers, and industry experts to drive collaboration and innovation. AMRA was proud to be among this year’s delegates, where we shared new insights from the CTRN-FSHD France Natural History Study—the largest FSHD natural history study to date.

We’re pleased to report that our own Markus Karlsson, PhD, presented results from a study titled “Natural History of Muscle Volume and Muscle Fat Content Biomarkers in FSHD Based on Whole-Body Fat-Referenced MRI.” Delivered as a featured oral presentation on Day 2, the talk highlighted that fat-referenced MRI biomarkers targeting intermediate muscles show significantly greater one-year progression in FSHD patients, underscoring their potential as sensitive, responsive markers in FSHD trials.

Our first poster presentation, “Quantitative Whole-Body MRI Biomarker Relation to Muscle Strength and Function in FSHD Patients,” demonstrated that AMRA’s whole-body MRI biomarkers, particularly lean muscle volume (LMV), strongly correlate with muscle function in FSHD patients, supporting their use as objective, reliable measures for assessing treatment effects in clinical trials.

The second poster, “Associations Between Muscle Strength and MRI Biomarkers in FSHD: Toward Imaging-Based Functional Classification,” showed that muscles with normal-appearing MRI features accurately identified clinically functioning muscles in FSHD patients, adding to the growing evidence base for MRI’s value as a surrogate biomarker in FSHD trials.

Last but certainly not least, our collaborator Ian Woodcock of Murdoch University shared results from “Whole-Body Muscle MRI in Children: Two-Year Follow-Up of the iFSHD-LOS Cohort.” This research showcases the utility and importance of AMRA biomarkers in a pediatric FSHD population.

If we missed you last week, reach us anytime at info@amramedical.com to learn more about how we’re using MRI-based methodologies to move disease research forwards in FSHD and beyond! AMRA is committed to helping pioneer the next wave of neuromuscular disease trials by delivering MRI-based biomarkers and advanced analytics – such as our composite scores – that enable standardized evaluation across clinical research efforts; including in heterogenous, hard-to-quantify populations such as FSHD.

As always, we truly enjoyed connecting with the broader FSHD community, and we look forward to continuing to make an impact as we move neuromuscular disease research forward together!

17/06/2025

A newly-published study, led by Mattias Ekstedt’s ectopic fat study group at the Department of Health, Medicine and Caring Sciences at Linköpings universitet (LiU), utilized AMRA’s MRI-based measures to find that six out of ten patients with type 2 diabetes (T2D) had metabolic dysfunction-associated steatotic liver disease (MASLD).

As the T2D and obesity epidemics continue to gain prevalence in parallel, recognizing related, more serious conditions such as advanced liver disease is critical. This prospective study, published in the Journal of Internal Medicine, investigated the prevalence and severity of MASLD and advanced fibrosis in 308 patients with T2D attending annual check-ups at their primary health care center.

The investigators found that 59% of participants with T2D had MASLD, and 7% had suspected advanced fibrosis. Obesity was identified as a key risk factor of fibrotic MASLD; people with obesity were eight times more likely to show signs of advanced liver scarring. Participants with MASLD also had changes in heart function and body fat accumulation patterns. The presence of adverse muscle composition, defined as low muscle volume z-score and high muscle fat, was reported to be 16% in this patient group, compared to 11% in the general population.

These findings demonstrate that while MASLD is prevalent in primary care subjects with T2D, advanced liver disease is relatively rare in this setting; though, obesity significantly increases the risk of severe outcomes—including potential implications for cardiovascular health. To deepen understanding of liver disease trajectories in this population beyond the snapshot provided in the present study, the research team has also initiated 5-year follow-up acquisitions.

You can read the full study, titled “Evaluating the prevalence and severity of MASLD in patients with type 2 diabetes mellitus in primary care”, here.https://doi.org/10.1111/joim.20103

Read LiU’s exciting press release spotlighting this study and its findings here!
https://shorturl.at/QPB4k

02/06/2025

AMRA is growing🚀 Are you our next Clinical Project Coordinator? Join our team!

🔍 About the Role: The Operations department is responsible for onboarding new customers, running and monitoring the quality of AMRA’s services, and ensuring continuous delivery of high-quality measurements that meet our customers' expectations.

As a Clinical Project Coordinator, you will play a key role in the Operations team — responsible for onboarding new imaging sites and providing essential support to our Clinical Project Managers.

👉 Read more: https://amramedical.com/career/

30/05/2025

ContextVision and AMRA Medical Team Up to Advance Imaging in Liver Disease Diagnostics

We are excited to share that ContextVision, a medical imaging software leader, has entered into a new research collaboration with AMRA! The goal of the partnership is to advance diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) by improving imaging-based diagnostic solutions.

MASLD affects approximately one in four people globally, and is rapidly becoming one of the leading causes of chronic liver disease. The need for non-invasive, cost-effective diagnostic solutions is urgent—particularly as current methods often miss early stages of disease.

“As we build out our Data Quality business, partnerships like this are essential,” said Gerald Pötzsch, CEO of ContextVision.

“AMRA’s highly detailed MRI measurements add critical value to our clinical data pipeline. Together, we are moving closer to a new standard in liver disease diagnostics - non-invasive, accurate, and scalable.”

By integrating MRI and ultrasound technologies through this research effort, the collaboration aims to develop actionable, multi-parameter biomarkers to improve early detection and treatment planning for millions of patients.

You can learn more about the partnership and its goals by reading the full press release from ContextVision here: https://www.contextvision.se/contextvision-and-amra-medical-join-forces-to-advance-multimodal-imaging-in-liver-disease-diagnostics/

21/05/2025

Join us! We are looking for our next Clinical Project Manager to join our team! 🚀

🔍 About the Role: The Clinical Project Manager is responsible for ensuring all projects are initiated, planned, executed, monitored/controlled, and closed out according to agreed-upon timelines, budgets and scopes. The Project Manager will collaborate with cross-functional teams including other departments to meet the project requirements and be accountable for the delivery of a high-quality service to our clients. Read more: https://amramedical.teamtailor.com/jobs/5948547-clinical-project-manager-to-amra-medical-ab

20/05/2025

AMRA Medical Returns to Its Roots at BME @ LiU 2025!

We’re excited to share that our very own Mikael Forsgren, PhD, will give an invited keynote at the 6th annual Biomedical Engineering Days at Linköping University (LiU)— the institution where AMRA’s journey began over 15 years ago! In the afternoon, Mikael and our friend and colleague – Mattias Ekstedt, MD, PhD, of the Department of Health, Medicine and Caring Sciences (HMV) – will together present their ongoing research on using MRI for diagnosis of patients with liver disease.

BME@LiU is a full day of talks, posters, exhibitions, and networking that brings together researchers, companies, students, clinicians, and organizations advancing or applying biomedical engineering technologies within the LiU community. AMRA is excited to share with the university community more about how our technology is shaping weight-reduction drug trials.

With the rise of GLP-1-based therapies transforming obesity treatment, the need for more meaningful and descriptive endpoints in clinical trials has never been greater. Mikael’s keynote will spotlight how AMRA’s MRI-derived z-score biomarkers—which quantify changes in fat distribution and muscle volume independent of s*x, height, weight, and BMI—provide researchers with reproducible, interpretable metrics that go beyond the scale, enabling a deeper understanding of treatment impact on body composition in clinical trials worldwide.

Born out of the Centre for Medical Image Science and Visualization (CMIV), AMRA is a prime example of globally-impactful biomedical innovation done right here at LiU – and we’re passionate and excited about inspiring the next generation of world-changers at this year’s BME Days!

🗓️ May 21 | 9:30 - 10:00 | General Session
🎤 Keynote Title: Reimagining MRI-Based Body Composition: A LiU Spin-Off is Shaping Weight-Reduction Drug Trials

🗓️ May 21 | 13:30 - 14:00 | Parallel Session, Medical Imaging and Visualization
🎤 Presentation title: Usage of whole-body composition when diagnosing liver patients

🔗 Learn more: https://liu.se/en/research/bme-conference/programme-and-speakers

13/05/2025

We are pleased to announce the highly-anticipated launch of our next-gen AMRA® BCP Scan service – powered by AMRA® Profiler 4! The device’s launch in Sweden and Germany marks the start of its availability in EU markets, and brings these powerful and unique biomarkers one step closer to patients everywhere. 🇸🇪 🇩🇪

The AMRA® BCP Scan service provides clinicians with fat distribution measurements, including liver fat, in addition to muscle composition biomarkers that comprise a detailed body composition profile (BCP) to assist in the assessment of health risks.

Find out how AMRA is changing the health risk assessment landscape in Sweden just days after launch by learning more about our collaboration with Elfcare. Read the full news article here: https://amramedical.com/amra-medical-launches-amra-profiler-4-in-sweden-and-germany-kickstarting-availability-campaign-of-amra-bcp-scan-service-in-the-eu/

09/05/2025

AMRA To Share Baseline Results from ACCESS-ESLD @ Gastrodagarna 2025!

If you’ll be in Stockholm from May 14-16th for Sweden’s own Gastrodagarna conference, make sure to stop by our poster, presented by the study PI Dr. Mattias Ekstedt from Linköping University, sharing the latest updates from the groundbreaking ACCESS-ESLD study, an ongoing collaborative research effort done in conjunction with our friends at Linköping University.

ACCESS-ESLD is a Swedish multi-center study led by Linköping University that includes 150 adult patients with liver cirrhosis undergoing hepatocellular carcinoma surveillance. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination, physical function testing, and a rapid whole-body MRI examination.

The study shows that adverse muscle composition, the combination of low muscle volume and high muscle fat, is a highly prevalent phenotype (20%) in this patient group. This population presented with higher frailty and poorer physical performance. In addition, those with high muscle fat, self-reported worse health status. These results underscore the importance of considering muscle fat alongside muscle volume to identify vulnerable sarcopenic patient groups within liver disease.

The study investigators hope that the findings of ACCESS-ESLD will continue the shift in management of liver disease towards employing more of a preemptive approach, by developing ways to monitor disease progression and severity while also identifying patients at risk for major adverse events or mortality.

Gastrodagarna is a yearly highlight-reel showcasing the latest in high-quality clinical care and research progress made in Swedish gastroenterology. The conference aims to bring together clinicians and researchers alike to continue weaving the strong fabric of Sweden’s gastroenterology community across academia, industry, and healthcare – and we’re excited to be in attendance year after year to help continue to shape liver disease care at home and abroad!

Come find our poster at Gastrodagarna, or connect with us at info@amramedical.com to learn more about how our use of MRI-based body composition analysis is advancing disease research in liver disease and beyond!

08/05/2025

🌍 AMRA Medical To Share Recent Findings in Sarcopenia and Obesity @ ECO 2025!

We're thrilled to announce that AMRA Medical will be attending and presenting findings at the 32nd European Congress on Obesity (ECO 2025) in Malaga, Spain from May 11th to the 14th! Join us as we present the latest AMRA research on sarcopenia in obesity and weight loss, most recently from a study that aims to investigate body size normalization from recent recommendations on definition and diagnosis of sarcopenic obesity.

Muscle mass is highly correlated with body size, and although people with obesity may have larger muscle mass in absolute terms, that amount may not be sufficient to carry their body weight and maintain mobility and function. Correcting for body size to make accurate judgements regarding muscle mass will help limit confounding results in both clinical trials and academic research within sarcopenia, obesity, and weight loss.

Attending ECO 2025? Let us know! Reach out to us via info@amramedical.com or get in touch via LinkedIn if you would like to connect with us in Spain.

To stay up-to-date on how AMRA is helping to drive research on sarcopenia and muscle changes in obesity and weight loss, keep up with our latest news here: https://shorturl.at/fuyLY

Adress

Badhusgatan 5
Linköping
58222

Öppettider

Måndag	09:00 - 17:00
Tisdag	09:00 - 17:00
Onsdag	09:00 - 17:00
Torsdag	09:00 - 17:00
Fredag	09:00 - 17:00

Telefon

+4613162600

Webbplats

http://www.amramedical.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när AMRA Medical postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till AMRA Medical:

Genvägar

Dela

Typ

Health/Medical/ Pharmaceuticals

Our Story

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.

Imbalances between muscle and fat are linked to a multitude of diseases and to some of the greatest challenges for patients and healthcare systems globally. A detailed understanding of body composition is, therefore, vital for identifying and tracking health and metabolic status, diseases or injuries, and overall fitness.

AMRA’s current research and application areas include Obesity, CVD, Diabetes, NAFLD/NASH, Oncology, Sarcopenia, Cachexia, CNS/Neuromuscular and Musculoskeletal Disorders, and Rare Diseases - in both adult and pediatric populations. Our Vision is a new, fundamental way of thinking about health. We provide knowledge to the medical community so that every individual can become — and stay — healthy.